Neuraworx Medical Technology, Inc., a neurotechnology company developing first-in-class bioelectronic solutions for brain health originally developed at the University of Wisconsin-Madison, today ...
InvestorsHub on MSN
CNS Pharmaceuticals shares dip after CEO departure announcement
Shares of CNS Pharmaceuticals Inc. (NASDAQ:CNSP) slipped 2.8% on Wednesday after the company disclosed that its Chief ...
Detailed price information for Cns Pharmaceuticals Inc (CNSP-Q) from The Globe and Mail including charting and trades.
- CANDID-CNS TM achieves an 83% success rate for predicting small molecule brain penetration and distribution versus a 64% success rate for the industry standard CNS-MPO score - Only ~2% of small ...
Secondary CNS lymphoma happens when non-Hodgkin’s lymphoma spreads to the brain, spinal cord, or eyes. Its symptoms depend on the areas of the CNS that are affected. The outlook for people with this ...
CANDID-CNS™ is the new state-of-the-art AI model for BBB penetration: it achieves 87% AUPRC on bRo5 small molecules compared to 56% by Pfizer’s CNS MPO.CANDID-CNS™ distinguishes CNS penetrant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback